Evidence map›Paper›PMID 29990573›Full record

ArticleUrology2018

National Trends in Active Surveillance for Prostate Cancer: Validation of Medicare Claims-based Algorithms.

Parth K Modi, Samuel R Kaufman, Ji Qi, Brian R Lane, Michael L Cher, David C Miller, Brent K Hollenbeck, Vahakn B Shahinian, James M Dupree

Abstract readValidation Study
In one paragraph

Article in Urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Parth K ModiDow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI. Electronic address: pamodi@med.umich.edu.
Samuel R KaufmanDow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI. Electronic address: skaufman@med.umich.edu.
Ji QiDow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI. Electronic address: qiji@med.umich.edu.
Brian R LaneUrologic Oncology, Spectrum Health, Grand Rapids, MI. Electronic address: Brian.Lane@spectrumhealth.org.
Michael L CherDepartment of Urology, Wayne State University, Detroit, MI. Electronic address: mcher@med.wayne.edu.
David C MillerDow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI. Electronic address: dcmiller@med.umich.edu.
Brent K HollenbeckDow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI. Electronic address: bhollen@med.umich.edu.
Vahakn B ShahinianDivision of Nephrology, Department of Medicine, University of Michigan, Ann Arbor, MI. Electronic address: vahakn@med.umich.edu.
James M DupreeDow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI. Electronic address: jmdupree@med.umich.edu.

Funding

Advanced Training in Urologic OncologyT32CA180984 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu, VAHAKN B SHAHINIAN · 2014 to 2026
$3.4M
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spendingR01HS025707 · AHRQ · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLLENBECK, BRENT K., SHAHINIAN, VAHAKN B · 2017 to 2021
$1.7M
Impact of Urologist Practice Structure on Prostate Cancer CareR01CA168691 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLLENBECK, BRENT K., SHAHINIAN, VAHAKN B · 2013 to 2016
$1.6M
AHRQ HHS R01 HS025707NCI NIH HHS R01 CA168691NCI NIH HHS T32 CA180984
6 · The paper itself

Abstract

objectiveTo better describe the real-world use of active surveillance. Active surveillance is a preferred management option for low-risk prostate cancer, yet its use outside of high-volume institutions is poorly understood. We created multiple claims-based algorithms, validated them using a robust clinical registry, and applied them to Medicare claims to describe national utilization. MATERIALS AND

methodsWe identified men with prostate cancer from 2012-2014 in a 100% sample of Michigan Medicare data and linked them with the Michigan Urologic Surgery Improvement Collaborative (MUSIC) registry. Using MUSIC treatment assignment as the standard, we determined the performance of 8 claims-based algorithms to identify men on active surveillance. We selected 3 algorithms (the most sensitive, the most specific, and a balanced algorithm incorporating age and comorbidity) and applied them to a 20% national Medicare sample to describe national trends.

resultsWe identified 1186 men with incident prostate cancer and completely linked data. Eight algorithms were tested with sensitivity ranging from 23.5% to 88.2% and specificity ranging from 93.5% to 99.1%. We found that the use of surveillance for men with incident prostate cancer increased from 2007 to 2014, nationally. However, among all men in the population, there was a large decrease in the rate of prostate cancer diagnosis and an increased or stable rate in the use of active surveillance, depending on the algorithm used. Less than 25% of men on active surveillance underwent a confirmatory prostate biopsy.

conclusionWe describe the performance of claims-based algorithms to identify active surveillance.

Indexed as

AftercareAgedAlgorithmsHumansMaleMedicareMichiganProstateProstatic NeoplasmsRegistriesSensitivity and SpecificityUnited StatesWatchful Waiting

Identifiers

PMID29990573
PMCPMC6462187

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.